Business Context and Reporting Period
Company: Spherix Incorporated (Note: Request metadata listed "Dominari Holdings Inc." but the filing text identifies the registrant as Spherix Incorporated).
Filing Type: Form 10-Q (Quarterly Report).
Reporting Period: Quarter and nine months ended September 30, 2004.
Operations: The Company operates two segments: InfoSpherix (contact center and reservation services, primarily for government clients) and BioSpherix (proprietary product development, notably tagatose/Naturlose). InfoSpherix generates substantially all continuing revenue.
Key Financial Metrics
| Metric | 3 Months Ended Sep 30, 2004 | 9 Months Ended Sep 30, 2004 |
|---|---|---|
| Revenue | $7,091,235 | $18,905,230 |
| Net Income (Loss) | $293,622 | $(61,522) |
| EPS (Diluted) | $0.02 | $(0.01) |
| Operating Cash Flow | N/A | $(130,658) Used |
| Cash and Equivalents | $4,419,955 | $4,419,955 |
| Working Capital | $6,889,325 | $6,889,325 |
| Debt (Bank Line of Credit) | $1,874,071 | $1,874,071 |
Note: Operating cash flow is reported for the nine-month period only in the source text.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 39% ($2.0M) for the quarter and 32% ($4.6M) for the nine months compared to 2003, driven by new government contracts and the acquisition of Daksoft, Inc. assets.
- Profitability Turnaround: The Company reported a net income of $294,000 for the quarter, reversing a net loss of $115,000 in the same period in 2003. For the nine months, the net loss narrowed significantly to $62,000 from $1.25 million in 2003.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 26% for the quarter and 15% for the nine months, primarily due to reduced legal expenses following the November 2003 arbitration settlement with Arla Foods.
- Investing Activity: Cash used in investing activities increased to $3.5 million (nine months) due to the purchase of Daksoft assets ($700,000) and significant property/equipment additions for facility relocation.
Guidance, Outlook, and Risks
- Contract Outlook: The Company won a multi-million dollar Federal Retirement Thrift Investment Board (FRTIB) contract and re-competed successfully for Maryland State agency contracts. However, the National Park Service (NPS) contract, representing 18% of YTD revenue, was awarded to a competitor; Spherix has filed a protest and currently operates under an extension through December 12, 2004.
- BioSpherix Progress: Tagatose (Naturlose) has received regulatory approvals in New Zealand, Australia, and from JECFA. The first pharmaceutical sale of Naturlose was completed in October 2004. Royalties remain modest pending the construction of a larger production plant by licensee Arla Foods.
- Liquidity: Working capital increased to $6.9 million. The Company has a $2 million bank line of credit with $126,000 remaining available. No dividends are anticipated.
- Accounting Correction: Net income reported in this filing is $40,000 lower than previously announced in a November 10, 2004 press release due to the proper accrual of a third-quarter expense.
Investor Verification Checklist
- NPS Contract Status: Verify the outcome of the protest regarding the National Park Service contract award, as this represents a significant revenue concentration risk.
- Tagatose Production Capacity: Confirm the timeline for Arla Foods' new plant construction, as this is the primary constraint on royalty revenue growth.
- Debt Covenants: Review the terms of the Bank of America line of credit renewal (expires June 30, 2005) and any potential covenants related to the recent facility relocation costs.
- Commercial Contract Decline: Monitor the continued decline in commercial (non-government) contracts, which decreased 88% in the quarter, to assess reliance on government funding.